STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

BioMarin (NASDAQ: BMRN) said its management team will present at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025 at 10:30 AM GMT in London, England. An audio webcast will be available live and an archived version of the remarks will be posted on the company investor website for a limited time.

Investors can access the live webcast and archive at https://investors.biomarin.com/.

BioMarin (NASDAQ: BMRN) ha annunciato che il suo team dirigenziale terrà una presentazione alla Jefferies Global Healthcare Conference martedì 18 novembre 2025 alle 10:30 GMT a Londra, Regno Unito. Verrà disponibile una trasmissione audio in diretta e una versione registrata dei lavori sarà pubblicata sul sito degli investitori dell'azienda per un periodo limitato.

Gli investitori possono accedere alla webcast in diretta e all'archivio su https://investors.biomarin.com/.

BioMarin (NASDAQ: BMRN) dijo que su equipo de dirección presentará en la Jefferies Global Healthcare Conference el martes 18 de noviembre de 2025 a las 10:30 AM GMT en Londres, Inglaterra. Se podrá escuchar una transmisión de audio en vivo y se publicará una versión archivada de las intervenciones en el sitio web de inversores de la empresa durante un tiempo limitado.

Los inversores pueden acceder al webcast en vivo y al archivo en https://investors.biomarin.com/.

BioMarin(나스닥: BMRN)은 경영진이 Jefferies Global Healthcare Conference에서 2025년 11월 18일 화요일 오전 10:30 GMT에 런던, 영국에서 발표할 것이라고 밝혔습니다. 실시간 오디오 웹캐스트가 제공될 것이며 발언의 아카이브 버전은 일정 기간 회사의 투자자 웹사이트에 게시될 예정입니다.

투자자들은 라이브 웹캐스트와 아카이브에 https://investors.biomarin.com/에서 접속할 수 있습니다.

BioMarin (NASDAQ: BMRN) a annoncé que son équipe de direction présentera lors de la Jefferies Global Healthcare Conference le mardi 18 novembre 2025 à 10 h 30 GMT à Londres, Royaume-Uni. Une diffusion audio en direct sera disponible en direct et une version archivée des remarques sera publiée sur le site Web des investisseurs de l'entreprise pour une durée limitée.

Les investisseurs peuvent accéder à la diffusion en direct et à l’archive sur https://investors.biomarin.com/.

BioMarin ( NASDAQ: BMRN) gab bekannt, dass sein Führungsteam bei der Jefferies Global Healthcare Conference am Dienstag, den 18. November 2025, um 10:30 Uhr GMT in London, Großbritannien, präsentieren wird. Ein Live-Audio-Webcast wird verfügbar sein und eine archivierte Version der Bemerkungen wird für einen begrenzten Zeitraum auf der Investoren-Website des Unternehmens veröffentlicht.

Investoren können den Live-Webcast und das Archiv unter https://investors.biomarin.com/ aufrufen.

قالت BioMarin (بورصة ناسداك: BMRN) إن فريق إدارتها سيقدم عرضاً في مؤتمر Jefferies للرعاية الصحية العالمية يوم الثلاثاء 18 نوفمبر 2025 الساعة 10:30 صباحاً بتوقيت GMT في لندن، إنجلترا. سيكون هناك بث صوتي مباشر متاح وسيتم نشر نسخة مؤرشفة من الملاحظات على موقع المستثمرين بالشركة لمدة محدودة.

يمكن للمستثمرين الوصول إلى البث المباشر والمؤرشفة في https://investors.biomarin.com/.

Positive
  • None.
Negative
  • None.

SAN RAFAEL, Calif., Nov. 11, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England in London.

An audio webcast of the presentation will be available live. The webcast can be accessed at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference. 

About BioMarin
BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin pursues treatments that offer new possibilities for patients and families around the world navigating rare or difficult-to-treat genetic conditions. To learn more, please visit www.biomarin.com.

Contacts:


Investors                           

Media

Traci McCarty                   

Marni Kottle

BioMarin Pharmaceutical Inc.               

BioMarin Pharmaceutical Inc.

(415) 455-7558                                       

(650) 374-2803

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-participate-at-the-jefferies-global-healthcare-conference-on-tuesday-november-18-2025-at-1030-am-gmt-in-london-england-302610867.html

SOURCE BioMarin Pharmaceutical Inc.

FAQ

When will BioMarin (BMRN) present at the Jefferies Global Healthcare Conference?

BioMarin management will present on Tuesday, November 18, 2025 at 10:30 AM GMT in London.

How can I listen to the BioMarin (BMRN) presentation on November 18, 2025?

An audio webcast will be available live at https://investors.biomarin.com/.

Will BioMarin (BMRN) provide a replay of the Jefferies conference presentation?

Yes. An archived version of the remarks will be posted on the company website for a limited time after the conference.

What time is the BioMarin (BMRN) webcast for U.S. investors on November 18, 2025?

The presentation is at 10:30 AM GMT; U.S. investors should convert that to their local time zones.

Where can investors find additional details about BioMarin (BMRN) conference participation?

Details and access to the live webcast and archive are available at https://investors.biomarin.com/.
Biomarin Pharmaceutical Inc

NASDAQ:BMRN

BMRN Rankings

BMRN Latest News

BMRN Latest SEC Filings

BMRN Stock Data

10.12B
190.62M
0.78%
98.97%
3.1%
Biotechnology
Pharmaceutical Preparations
Link
United States
NOVATO